narsoplimab (Pending FDA Approval)

Brand and Other Names:
  • Print

Dosing & Uses

Hematopoietic Stem Cell Transplant-associated Thrombotic Microangiopathy

Pending FDA approval for hematopoietic stem cell transplant-associated thrombotic microangiopathy (HSCT-TMA)

Next:

Pharmacology

Mechanism of Action

Human monoclonal antibody targeting mannan-binding lectin-associated serine protease-2 (MASP-2), the effector enzyme of the lectin pathway of the complement system

Lectin pathway is a principal pathway of complement and is activated primarily by tissue damage and microbial infection; notably, MASP-2 inhibition appears not to interfere with the complement pathway, an essential component of the acquired immune response to infection

The drug is designed to prevent complement-mediated inflammation and endothelial damage while leaving intact the respective functions of the other pathways of innate immunity

Previous
Next:

Images

No images available for this drug.
Previous
Next:

Patient Handout

A Patient Handout is not currently available for this monograph.
Previous
Medscape prescription drug monographs are based on FDA-approved labeling information, unless otherwise noted, combined with additional data derived from primary medical literature.